세계의 듀테트라베나진(Deutetrabenazine) 시장 : 규모, 점유율, 성장, 산업 분석, 유형별, 용도별, 지역별 인사이트, 예측(2024-2032년)

Growth Factors of deutetrabenazine Market

The global deutetrabenazine market continues strong upward momentum, driven by rising diagnosis of neurological disorders and broader regulatory approvals. Valued at USD 1.69 billion in 2024, the market is projected to grow to USD 2.03 billion in 2025 and further reach USD 5.42 billion by 2032. A robust CAGR of 15.1% during 2025-2032 reflects expanding applications, increasing disease awareness, and the strong performance of approved VMAT2 inhibitors.

The market is significantly dominated by North America, which accounted for 94.08% of global share in 2024, supported by a high prevalence of Huntington's disease (HD) and tardive dyskinesia (TD), strong healthcare infrastructure, ongoing awareness programs, and early regulatory approvals. Deutetrabenazine, primarily commercialized under the brand name AUSTEDO by Teva Pharmaceutical Industries Ltd., remains patent-protected, limiting generic competition and strengthening Teva's market dominance.

Market Dynamics

Market Growth Drivers

Rising cases of neurodegenerative disorders-especially HD and TD-remain the strongest driver for deutetrabenazine adoption. Greater access to genetic testing, improved clinical awareness, and early diagnosis enable timely therapeutic intervention. For instance, the Rare Disease Advisory reported in 2023 that HD prevalence in North America reached 8.87 per 100,000 population, highlighting the growing patient pool requiring long-term VMAT2 inhibitor therapy.

Increasing research investments and pharmaceutical focus on new formulations further support market expansion. Broader acceptance of deutetrabenazine in treatment guidelines across major healthcare systems is also fueling uptake.

Market Restraints

Despite rising adoption, market growth is affected by manufacturing complexities. The deuteration process, which slows drug metabolism and enhances efficacy, also increases production costs-reducing affordability in emerging markets. Long-term safety concerns may also hinder sustained therapy use.

Regulatory hurdles, including rigorous EMA and FDA post-marketing surveillance requirements, extend approval timelines for new indications and formulations, delaying broader commercialization.

Market Opportunities

A major opportunity lies in extended-release (XR) formulations. Teva's AUSTEDO XR, launched in May 2024, introduced once-daily dosing convenience, improving patient adherence and supporting prescription growth. Pharmaceutical companies are also leveraging lifecycle management strategies, including new dosing strengths, geographic expansion, and broader clinical trials targeting additional neurological disorders.

Growth potential in Asia Pacific, particularly in China, South Korea, and India, remains strong due to rising diagnosis rates and increasing accessibility. China's NMPA approval of AUSTEDO in May 2020 significantly opened the region for expansion.

Market Challenges

Competition from alternative VMAT2 inhibitors such as tetrabenazine (Xenazine) and valbenazine (Ingrezza) presents ongoing market pressure. These drugs offer different dosing regimens and side-effect profiles, influencing prescriber preference and pricing competition.

Market Trends

A prominent trend is geographical expansion, with companies pushing for approvals and commercial partnerships across Europe, Asia Pacific, and Latin America. Strategic patent filings continue to protect market exclusivity, with generic competition unlikely before 2030.

Growing patient advocacy campaigns-especially regarding TD awareness-are also improving diagnosis and boosting treatment adoption. Additionally, clinical investments targeting broader neurological indications like Tourette syndrome present future growth opportunities.

Segmentation Analysis

By Application

• Tardive Dyskinesia (TD) held the largest share in 2024 due to high prevalence and growing awareness. TD Awareness Week in the U.S. underscores this trend.
• Huntington's Disease (HD) is expected to grow rapidly due to rising R&D efforts and earlier diagnosis through genetic testing.

By Distribution Channel

• Hospital pharmacies dominated in 2024 given the prescription-only status of deutetrabenazine.
• Retail pharmacies & drug stores are expected to expand as more pharmacies stock specialty neurological drugs.

Regional Highlights

North America (USD 1.59 billion in 2024)

The region leads globally due to early adoption, high disease prevalence, substantial R&D spending, and strong presence of Teva Pharmaceuticals. The U.S. continues to drive market demand supported by awareness programs and advanced neurology centers.

Europe

Rising public healthcare spending, EMA approvals, and growing prevalence of HD (6.37 per 100,000 individuals in 2023) contribute to the region's steady expansion.

Asia Pacific

The region is poised for significant growth due to increasing regulatory approvals, better diagnostics, and expanding neurological care infrastructure.

Rest of World

Growth remains modest due to lower disease awareness and limited neurology infrastructure.

Conclusion

The deutetrabenazine market's rise-from USD 1.69 billion in 2024 to a projected USD 5.42 billion by 2032-shows strong momentum fueled by increasing diagnosis of neurodegenerative disorders, introduction of XR formulations, and robust expansion efforts by Teva. Continued regulatory approvals and clinical innovations will remain central to future market growth.

Segmentation By Application

• Huntington's Disease
• Tardive Dyskinesia
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

By Region

• North America (By Application, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Application, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific (By Application, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Rest of the World (By Application and Distribution Channel)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Epidemiology of Key Diseases
• 4.2. Regolatory Scenario, By Key Countries/Regions
• 4.3. Reimbursement Scenario, By Key Countries/Regions
• 4.4. Pipeline Analysis, By Key Players
• 4.5. Key Industry Developments (Mergers, Acquisitions, and Collaborations etc.)
• 4.6. New Product Launches, By Key Players

5. Global Deutetrabenazine Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Application
  • 5.1.1. Huntington's Disease
  • 5.1.2. Tardive Dyskinesia
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.2.1. Hospital Pharmacies
  • 5.2.2. Retail Pharmacies & Drug Stores
  • 5.2.3. Online Pharmacies
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Rest of the World

6. North America Deutetrabenazine Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Application
  • 6.1.1. Huntington's Disease
  • 6.1.2. Tardive Dyskinesia
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.2.1. Hospital Pharmacies
  • 6.2.2. Retail Pharmacies & Drug Stores
  • 6.2.3. Online Pharmacies
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Deutetrabenazine Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Application
  • 7.1.1. Huntington's Disease
  • 7.1.2. Tardive Dyskinesia
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.2.1. Hospital Pharmacies
  • 7.2.2. Retail Pharmacies & Drug Stores
  • 7.2.3. Online Pharmacies
• 7.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.3.1. K.
  • 7.3.2. Germany
  • 7.3.3. France
  • 7.3.4. Spain
  • 7.3.5. Italy
  • 7.3.6. Rest of Europe

8. Asia Pacific Deutetrabenazine Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Application
  • 8.1.1. Huntington's Disease
  • 8.1.2. Tardive Dyskinesia
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.2.1. Hospital Pharmacies
  • 8.2.2. Retail Pharmacies & Drug Stores
  • 8.2.3. Online Pharmacies
• 8.3. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.3.1. Japan
  • 8.3.2. China
  • 8.3.3. India
  • 8.3.4. Australia
  • 8.3.5. Rest of Asia Pacific

9. Rest of the World Deutetrabenazine Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Application
  • 9.1.1. Huntington's Disease
  • 9.1.2. Tardive Dyskinesia
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.2.1. Hospital Pharmacies
  • 9.2.2. Retail Pharmacies & Drug Stores
  • 9.2.3. Online Pharmacies

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2024)
• 10.2. Company Profiles
  • 10.2.1. Teva Pharmaceutical Industries Ltd.
    • 10.2.1.1. Overview
    • 10.2.1.2. Products & services
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. Other Prominent Players
    • 10.2.2.1. Overview
    • 10.2.2.2. Products & services
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)